Abstract
Background: Guselkumab (GUS) is effective in treating moderate to severe psoriasis. Here, we characterized the baseline profile of patients with moderate to severe psoriasis achieving superresponse (defined as patients who achieved a Psoriasis Severity and Area Index [PASI] 100 response at both weeks 20 and 28) with GUS treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
